单纯疱疹病毒1型囊膜糖蛋白gD在大肠杆菌中的表达、纯化及其免疫活性的鉴定

目的:在大肠杆菌中表达1型单纯疱疹病毒(HSV-1)囊膜糖蛋白gD,纯化重组蛋白并对其免疫活性进行鉴定。方法:将HSV-1 gD 基因克隆入原核表达载体pET-28b,利用异丙基-B-D-硫代吡喃半乳糖苷(IPTG)诱导重组质粒转化的大肠杆菌,探讨IPTG浓度、诱导时间、诱导温度对重组蛋白表达的影响;盐酸胍裂解变性包涵体,镍柱亲和层析法纯化gD蛋白,并对纯化后的蛋白进行透析复性;Western blot和ELISA检测gD蛋白的免疫活性。结果:酶切和测序结果表明gD基因克隆入pET-28b载体。该重组质粒转化的大肠杆菌经IPTG诱导后重组蛋白主要以包涵体形式存在,大小约40kDa。gD蛋白诱导表达的最佳条件为0.5mmol/L IPTG于37℃诱导8h。镍柱亲和层析法纯化获得的gD蛋白总量为3.1mg/L,透析复性后获得的gD蛋白总量为1.3mg/L,复性率为41.37%。Western blot及ELISA检测表明表达的gD蛋白具有免疫活性。结论:在大肠杆菌中表达并纯化获得具有免疫活性的HSV-1 gD蛋白,为进一步制备HSV-1诊断试剂和预防疫苗奠定了基础。     

水稻几丁质酶基因在大肠杆菌中的表达、纯化与活性分析

将克隆并确定序列的水稻(Oryza sativa L．Cpslo17)几丁质酶基因Oschi的cDNA序列(此序列已在GenBank中注册, 登录号为EU045451)插入原核表达载体pGEX-4T-1中。经酶切、序列鉴定分析后, 用该重组质粒转化大肠杆菌BL21(DE3); 经IPTG诱导获得表达, 并对Oschi蛋白表达条件进行了优化; 在大肠杆菌中表达的几丁质酶经纯化后在一定的浓度、一定的反应时间内能高效地分解几丁质。     

米曲霉中蓝藻抗病毒蛋白-N基因的克隆与表达

[目的]提高蓝藻抗病毒蛋白-N(CVN)的异源表达量,获得大量高纯度可溶性蛋白。[方法]采用RT-PCR从酱油发酵酱醪宏基因组中克隆获得CVN基因cvn-SF,构建了重组表达载体p ET32a-cvn-SF,转化E.coli BL21菌株,获得工程菌株,优化表达条件,通过Ni-NTA凝胶亲和层析对CVN-SF蛋白进行纯化。[结果]工程菌株在温度30℃、添加1 mmol/L的IPTG诱导剂、培养时间12 h的条件下获得最高表达量的可溶性蛋白。Ni-NTA凝胶亲和层析纯化得到了230.8 mg/L的CVN蛋白,占提取总蛋白含量的33.37%。[结论]所得CVN蛋白高于目前报道的CVN在大肠杆菌的最高表达量140 mg/L~([11])。     

稀有密码子影响人RNaseH-Apaf1融合蛋白原核表达

通过限制性内切酶克隆法构建两个pET-28a-TAT-RNaseH-Apaf1重组质粒,其中一个质粒经过稀有密码子的优化。将两个重组质粒分别转化原核表达宿主菌BL21(DE3)和Transetta(DE3),通过SDS-PAGE观察相应融合蛋白诱导表达的情况,并用His标签抗体和Apaf1抗体通过Western Blotting鉴定诱导蛋白。菌液PCR和测序证明经稀有密码子优化和未经稀有密码子优化的人源RNaseH-Apaf1序列成功重组到pET-28a-TAT载体中;经稀有密码子优化的重组质粒成功地在大肠杆菌宿主菌中表达RNaseH-Apaf1融合蛋白,并用Western Blotting检测到该融合蛋白。结果表明,稀有密码子可影响人RNaseH-Apaf1融合蛋白的原核表达。     

水稻几丁质酶基因在大肠杆菌中的表达、纯化与活性分析

将克隆并确定序列的水稻(Oryza sativa L．Cpslo17)几丁质酶基因Oschi的cDNA序列(此序列已在GenBank中注册, 登录号为EU045451)插入原核表达载体pGEX-4T-1中。经酶切、序列鉴定分析后, 用该重组质粒转化大肠杆菌BL21(DE3); 经IPTG诱导获得表达, 并对Oschi蛋白表达条件进行了优化; 在大肠杆菌中表达的几丁质酶经纯化后在一定的浓度、一定的反应时间内能高效地分解几丁质。     

Angioarrestin(hARP1)C端FD区的克隆、表达及其免疫活性鉴定

Angioarrestin是一种具有潜在应用价值的肿瘤血管形成抑制因子.利用DNA重组法构建了angioarrestinC端hFDcDNA和麦芽糖结合蛋白(MBP)重组原核表达质粒pMAL-C2-hFD.将重组质粒转入大肠杆菌E.coliBL21(DE3),经0.3mmol/LIPTG在37℃条件下诱导表达4h,SDS-PAGE检测,融合蛋白表达量约占细菌总蛋白的20%.Western印迹证实,目的蛋白N端带有MBP标签.取表达上清纯化、透析、浓缩并冻干,以此为抗原免疫Balb/c小鼠制备多克隆抗体.此多抗可以与pET-22b( )表达系统获得的hFD重组蛋白发生良好的抗原抗体反应,ELISA检测多抗效价达1∶10240.实验证明:通过基因重组可获得angioarrestinC端hFD在大肠杆菌中的高效表达蛋白,且该蛋白具有较高的免疫活性.以此为抗原制备的抗angioarrestin多克隆抗体为深入研究angioarrestin提供了材料.     

重组人干扰素λ1的表达、纯化及生物活性研究

目的:利用大肠杆菌系统表达重组人Ⅲ型干扰素λ1(rhIFN-λ1),并进行纯化,以比较其与重组人干扰素-α2b(rhIFN-α2b)生物学活性的差异。方法:密码子优化的rhIFN-λ1基因与pET-44a载体连接构建原核表达质粒,在大肠杆菌BL21(DE3)中表达,表达产物经系列层析纯化;采用细胞病变抑制法比较纯化的rhIFN-λ1与rhIFN-α2b、市售rhIFN-λ1的抗病毒活性;采用MTS法比较这些干扰素的抗肿瘤细胞增殖活性。结果:基因优化后的rhIFN-λ1在大肠杆菌中得以高效表达,用所建立的纯化工艺可制备得到纯度达95.7%的rhIFN-λ1;rhIFN-λ1的抗病毒比活性为3.2×105 U/mg,比市售rhIFN-λ1的比活性(1.1×105 U/mg)略高,抗肿瘤细胞增殖活性为rhIFN-α2b的1.7倍。结论:获得的rhIFN-λ1具有剂量依赖的抗病毒活性和抗增殖活性,其抗病毒活性比市售rhIFN-λ1略高,抗细胞增殖活性高于rhIFN-α2b,提示rhIFN-λ1有较大的应用前景。     

蛇毒蛋白triflin功能区TFPR1在大肠杆菌中的表达及其功能初步研究

目的:获得具有生物学活性的蛇毒蛋白triflin的致病相关蛋白1(PR-1)功能区TFPR1。方法:分析triflin空间结构及其保守结构域,获得TFPR1序列,并进行密码子优化、全基因合成,构建原核表达质粒p ET-TFPR1,在大肠杆菌BL21中以IPTG诱导表达,表达产物经Western印迹鉴定后,镍柱纯化、复性,对复性后的产物进行特性分析;以复性的TFPR1肌肉途径接种BALB/c雌性小鼠,分析其生物学活性。结果:TFPR1以包涵体形式表达,复性后蛋白纯度大于95%,无需佐剂免疫小鼠即可诱导机体产生效价为20万的抗TFPR1抗体。结论:制备了具有生物学活性的重组蛋白TFPR1,为后续研究TFPR1的生物学功能奠定了物质基础。     

人蛋白酶体亚基PSMB1的重组表达、纯化及在蛋白酶体抑制剂体外筛选中的应用

蛋白酶体是真核细胞中的一类多亚基蛋白酶复合物,它在胞内蛋白质降解的泛素-蛋白酶体通路中起关键作用。重组表达蛋白酶体的活性亚基可以用于在体外筛选、寻找具有蛋白酶体抑制剂作用的化合物。将人蛋白酶体催化亚基(PSMB1)cDNA的编码区(全长726 bp)克隆至原核表达载体pET28a(+),构建重组质粒pET28a-PSMB1,转化大肠杆菌BL21(DE3),通过1 mmol/L IPTG,20℃过夜诱导,获得相对分子量约为27 kDa的重组蛋白,采用IMAC亲和层析柱纯化重组蛋白,纯化后的重组蛋白纯度超过95%。重组蛋白酶解后经NanoLC-MS/MS鉴定表明所表达的融合蛋白氨基酸序列完全正确。在体外BIAcore分析中,重组蛋白表现出对不同化合物的选择性结合能力,其中与蛋白酶体抑制剂雷公藤红素的结合较强,10μmol/L的雷公藤红素与重组蛋白的结合达到27 RU,并且具有良好的浓度依赖型。本研究建立了表达、纯化人蛋白酶体催化亚基PSMB1的方法,并应用于具有蛋白酶体抑制活性化合物的体外筛选。     

猪抵抗素(resistin)表达载体的构建、表达及表达产物的纯化鉴定

用PCR方法扩增到抵抗素基因(RSTN)并将其亚克隆至pET-32a(+)表达载体,获得重组质粒pET-RSTN.将重组质粒转化大肠杆菌BL-21(DE3)感受态细胞,用IPTG诱导表达.SDS-PAGE检测结果表明,重组resistin蛋白分子量大小约30kDa.对表达条件如温度、IPTG浓度及诱导时间进行优化并用SDS-PAGE检测.结果表明,30℃、4h、IPTG浓度为1mmol/L时,可溶性重组resistin的含量最高.表达产物经Western blot检测证实是Resistin蛋白,并用镍离子亲和层析的方法获得纯化的Resistin蛋白.     

蓝藻抗病毒蛋白-N衍生物的克隆、发酵与纯化

蓝藻抗病毒蛋白-N( Cyanovirin-N,CVN)能特异性与病毒表面糖蛋白结合,抑制病毒进入宿主细胞及抑制病毒感染细胞与未感染细胞的融合.通过分子设计及优化,在CVN的N-末端连接了5个氨基酸的柔性多肽(GGGGS),构建了SUMO-L5-CVN融合表达系统.SUMO-L5-CVN在大肠杆菌BL21中呈可溶性表达;通过表达条件优化,以0.5 mmol/L IPTG在20℃诱导24h 是最佳的诱导表达条件;SUMO-L5-CVN表达量占菌体总蛋白的30％;经Ni-NTA亲和层析获得融合蛋白SUMO-L5-CVN,SUMO蛋白酶酶切,以及进一步从Ni-NTA亲和层析获得的目的蛋白L5-CVN蛋白纯度＞98％.结果表明,低浓度的L5-CVN与流感病毒表面糖蛋白gp120就有较高的亲和力.     

A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions

The first, critical stage of HIV-1 infection is fusion of viral and host cellular membranes initiated by a viral envelope glycoprotein gp120. We evaluated the potential to form a chimeric protein entry inhibitor that combines the action of two gp120-targeting molecules, an allosteric peptide inhibitor 12p1 and a higher affinity carbohydrate-binding protein cyanovirin (CVN). In initial mixing experiments, we demonstrated that the inhibitors do not interfere with each other and instead show functional synergy in inhibiting viral cell infection. Based on this, we created a chimera, termed L5, with 12p1 fused to the C-terminal domain of CVN through a linker of five penta-peptide repeats. L5 revealed the same broad specificity as CVN for gp120 from a variety of clades and tropisms. By comparison to CVN, the L5 chimera exhibited substantially increased inhibition of gp120 binding to receptor CD4, coreceptor surrogate mAb 17b and gp120 antibody F105. These binding inhibition effects by the chimera reflected both the high affinity of the CVN domain and the allosteric action of the 12p1 domain. The results open up the possibility to form high potency chimeras, as well as noncovalent mixtures, as leads for HIV-1 envelope antagonism that can overcome potency limits and potential virus mutational resistance for either 12p1 or CVN alone.     

SUMO蛋白酶活性片段的表达、纯化及活性测定

利用PCR技术人工合成编码酿酒酵母泛素样特异性蛋白酶1 (Ubiquitin-like specific protease 1,Ulp1)第403到621个氨基酸残基之间的DNA片段Ulp1p,并连接到大肠杆菌表达载体pET-3c中,构建出重组表达质粒pET-Ulp1p。将重组质粒转化至大肠杆菌BL21(DE3)中,氨苄青霉素抗性筛选转化子。经IPTG诱导4h后, SDS-PAGE结果显示,Ulp1p为可溶性表达,表达量占菌体总蛋白的50.8%。通过Ni-NTA凝胶亲和层析和G-25凝胶层析联用可以获得纯度大于95%的Ulp1p。Western-blotting分析表明,Ulp1p能与6xHis抗体产生免疫反应。以重组蛋白SUMO-hEGF(人表皮生长因子)和GST-SUMO-MT(金属硫蛋白)为底物进行酶切分析,结果显示,Ulp1p能特异性水解这两种SUMO融合蛋白,其比活为1.386 x104U/mg。     

Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydrate-mediated binding to gp120

BACKGROUND: Cyanovirin-N (CVN) is a novel, 11 kDa cyanobacterial protein that potently inhibits viral entry by diverse strains of HIV through high-affinity carbohydrate-mediated interactions with the viral envelope glycoprotein gp120. CVN contains two symmetry-related carbohydrate binding sites of differing affinities that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinities, the carbohydrates that also mediate CVN:gp120 binding. High-resolution structural studies of CVN in complex with a representative oligosaccharide are desirable for understanding the structural basis for this unprecedented specificity. RESULTS: We have determined by multidimensional heteronuclear NMR spectroscopy the three-dimensional solution structure of CVN in complex with two equivalents of the disaccharide Manalpha1-2Manalpha, a high-affinity ligand which represents the terminal-accessible disaccharide present in Man(8) D1D3 and Man(9). The structure reveals that the bound disaccharide adopts the stacked conformation, thereby explaining the selectivity for Man(8) D1D3 and Man(9) over other oligomannose structures, and presents two novel carbohydrate binding sites that account for the differing affinities of the two sites. The high-affinity site comprises a deep pocket that nearly envelops the disaccharide, while the lower-affinity site comprises a semicircular cleft that partially surrounds the disaccharide. The approximately 40 A spacing of the two binding sites provides a simple model for CVN:gp120 binding. CONCLUSIONS: The CVN:Manalpha1-2Manalpha complex provides the first high-resolution structure of a mannose-specific protein-carbohydrate complex with nanomolar affinity and presents a new carbohydrate binding motif, as well as a new class of carbohydrate binding protein, that facilitates divalent binding via a monomeric protein.     

Production of recombinant peptides as fusions with SUMO

Recombinant production of non-native peptides requires using protein fusion technology to prevent peptide degradation by host-cell proteases. In this work, we have used SUMO protein as a fusion partner for the production of difficult-to-express, antimicrobial, self-assembling and amyloidogenic peptides using Escherichia coli. SUMO-peptide fusions were expressed as intracellular products by utilizing pET based expression vectors constructed by Life Sensors Inc., USA. Histidine tagged SUMO-peptide fusions were purified using Ni-NTA affinity chromatography. Complete (100%) cleavage of the SUMO-peptide fusion was achieved using SUMO protease-1. Our findings demonstrate that SUMO fusion technology is a promising alternative for production of peptides in E. coli. The key advantage of this technology is that the enzymatic activity of SUMO protease-1 is specific and efficient leading to inexpensive costs for cleaving the peptide fusion when compared with other fusion systems.     

SUMO蛋白酶的发酵和纯化工艺的研究

目前, 小分子肽多需要进行融合表达,虽然有GST标签等表达体系,但是表达产物切割时仍留有多余氨基酸,影响小分子肽的功能;SUMO蛋白酶对SUMO融合表达系统表达的重组蛋白进行切割时没有多余氨基酸残留,因此成为蛋白切割工具的热点。利用基因工程技术构建重组His-Ulp1/pET3c/BL21（DE3）工程菌株,用摇瓶优化表达条件,摸索高密度发酵工艺和不同层析纯化工艺条件。结果表明,经1.0mmol/L的IPTG 30℃诱导表达6h,表达效果最好。罐发酵后菌体SDSPAGE分析表达量可达24.39%,通过CM Sepharose Fast Flow阳离子交换一步层析可获得纯度大于98%的SUMO蛋白酶,每升发酵液可获得355mg的SUMO蛋白酶纯品。Western blot分析表明,UlP1能与6×His抗体产生免疫反应。为日后大规模产业化生产奠定了基础。     

HIV—1 P24截短体与gp41截短体的融合蛋白在大肠杆菌中的表达、纯化和鉴定

用基因重组技术将截短的HIV－1 p24基因和gp41基因连接成嵌合基因,插入质粒pGEX-4T3,构建成重组表达质粒pGEX-F。将pGEX-F转化大肠杆菌BL21。经IPTG诱导表达,pGEX-F在大肠杆菌BL21中获得了高效表达。融合蛋白P24－gp41经Glutathione-Sepharose4B亲和层析纯化后,用间接ELISA和免疫印迹检测HIV抗体阳性血清和正常人血清,P24－gp41只与HIV抗体阳性血清反应,证明获得的融合蛋白P24－gp41有很强的抗原特异性和免疫反应性,具有较高的应用价值。     

An improved SUMO fusion protein system for effective production of native proteins

Expression of recombinant proteins as fusions with SUMO (small ubiquitin-related modifier) protein has significantly increased the yield of difficult-to-express proteins in Escherichia coli. The benefit of this technique is further enhanced by the availability of naturally occurring SUMO proteases, which remove SUMO from the fusion protein. Here we have improved the exiting SUMO fusion protein approach for effective production of native proteins. First, a sticky-end PCR strategy was applied to design a new SUMO fusion protein vector that allows directional cloning of any target gene using two universal cloning sites (Sfo1 at the 5'-end and XhoI at the 3'-end). No restriction digestion is required for the target gene PCR product, even the insert target gene contains a SfoI or XhoI restriction site. This vector produces a fusion protein (denoted as His(6)-Smt3-X) in which the protein of interest (X) is fused to a hexahistidine (His(6))-tagged Smt3. Smt3 is the yeast SUMO protein. His(6)-Smt3-X was purified by Ni(2+) resin. Removal of His(6)-Smt3 was performed on the Ni(2+) resin by an engineered SUMO protease, His(6)-Ulp1(403-621)-His(6). Because of its dual His(6) tags, His(6)-Ulp1(403-621)-His(6) exhibits a high affinity for Ni(2) resin and associates with Ni(2+) resin after cleavage reaction. One can carry out both fusion protein purification and SUMO protease cleavage using one Ni(2+)-resin column. The eluant contains only the native target protein. Such a one-column protocol is useful in developing a better high-throughput platform. Finally, this new system was shown to be effective for cloning, expression, and rapid purification of several difficult-to-produce authentic proteins.     

重组人肿瘤坏死因子α抑制肽-抗炎酸性尾巴融合蛋白的生物学活性检测

目的：评价原核表达、纯化的6×His-硫氧还蛋白（TRX）一人肿瘤坏死因子α（TNFα）抑制肽-C端抗炎酸性尾巴融合蛋白的生物学功能。方法：在大肠杆菌中分别表达带His标签的TRX对照蛋白及TRX蛋白融合的人TNFα抑制肽-抗炎酸性尾巴融合蛋白,并对2种蛋白进行N^2＋金属螯合层析纯化,采用MTT法检测纯化后的蛋白及化学合成多肽抑制TNFα标准品对L929细胞的细胞毒活性。结果：与对照蛋白相比,融合蛋白人TNFα抑制肽-C端抗炎酸性尾巴及合成多肽均能拮抗TNFα标准品对L929细胞的细胞毒作用。结论：融合蛋白人TNFα抑制肽-C端抗炎酸性尾巴及合成肽均能有效拮抗TNFα的生物学作用,为今后发展抑制TNFα为主的抗炎生物药物奠定了基础。     

GST融合蛋白在杆状病毒系统中表达的可溶性研究

将构建好的可表达ＧＳＴ融合蛋白的重组病毒ＡｃＭＮＰＶ－ＯＣＣ＾－－ＧＳＴ－６ｘＨｉｓ－Ｅｔｐ２８感染Ｓｆ９细胞,一定时间后取感染了病毒的细胞裂解物上清液进行ＳＤＳ－ＰＡＧＥ分析,结果显示５３ｋＤａ的融合蛋白（ＧＳＴ－６ｘＨｉｓ－Ｅｔｐ２８）呈不溶状态。在原有裂解液的基础上,加固体十二烷基肌氨酸钠致终浓度１．５％,并将Ｔｒｉｔｏｎ Ｘ－１００的比例由１％提高到２％。ＳＤＳ－ＰＡＧＥ结果显示至少有１／